Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420601 | 0.75 | RNASEH1 (0.33) | RNASEH1 | |
| SCHEMBL19420581 | 0.74 | BAD (0.38) | HIF1ARNASEH1 | |
| SCHEMBL19420593 | 0.71 | UGT2B7 (0.32) | — | |
| SCHEMBL19426081 | 0.71 | TSHR (0.31) | TYRALDH1A1GAAALOX12HTT | |
| SCHEMBL19420587 | 0.61 | TRPA1 (0.42) | TYRALDH1A1GAAALOX12HTT | |
| SCHEMBL30360391 | 0.59 | TYR (0.44) | TYRALDH1A1GAAALOX12HTT | |
| SCHEMBL1760433 | 0.59 | TYR (0.44) | TYRALDH1A1GAAALOX12HTT | |
| SCHEMBL17192076 | 0.56 | — | — | |
| SCHEMBL13773184 | 0.54 | RNASEH1 (0.45) | TYRALDH1A1GAAALOX12HTT | |
| SCHEMBL172232 | 0.53 | TRPA1 (0.67) | TYRALDH1A1GAAALOX12HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174053-B2 | 2 substituted cephem compounds | GLAXO GROUP LIMITED (GB) | 2019-01-08 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | TYR 734/4885ALDH1A1 1437/4885GAA 31/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | TYR 318/4885ALDH1A1 3320/4885GAA 815/4885 |
| US-10174053-B2 | 2 substituted cephem compounds | CEP170, CES2, CMBL | TYR 734/4885ALDH1A1 1437/4885GAA 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.